Clinical trials: CHC
Hepatitis C
EDP-494-001: A Study of EDP-494 in Healthy Subjects and Hepatitis C Patients
This randomized, double-blind study will assess the safety, pharmacokinetics and efficacy of a single and multiple dose(s) of orally QD administered EDP-494 in healthy volunteers (HV) and in treatment-naive subjects with GT1/3…
- Trial name
- NCT02652377
- Testing
- EDP-494
- Where
- New Zealand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Enanta Pharmaceuticals, Inc
Hepatitis C, Chronic, Healthy Volunteer
A Study of RO5428029 in Healthy Volunteers and Patients With Chronic Hepatitis C
This 2-part, randomized, double-blind, placebo-controlled study will assess the safety, pharmacokinetics and pharmacodynamics of RO5428029 in healthy volunteers and patients with hepatitis C infection.
- Trial name
- NCT01371162
- Testing
- RO5428029
- Where
- 6 sites in France, Netherlands and 1 more
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche
Hepatitis C, Chronic
A First Time in Human Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single & Repeat Escalating Doses of GSK2878175 in Healthy Subjects
GSK2878175 is a site IV NS5B non-nucleoside inhibitor (NNI) being developed for the treatment of chronic HCV infection. This study represents the first administration of GSK2878175 in humans to define safety, tolerability, and…
- Trial name
- NCT01879462
- Testing
- GSK2878175
- Where
- Australia
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline